BioNote, Inc. (KRX:377740)
South Korea · Delayed Price · Currency is KRW 6,100.00
+430.00 (7.58%)
At close: Sep 8, 2025
BioNote Revenue
BioNote had revenue of 32.41B KRW in the quarter ending June 30, 2025, with 23.32% growth. This brings the company's revenue in the last twelve months to 112.04B, up 17.84% year-over-year. In the year 2024, BioNote had annual revenue of 102.78B with 14.10% growth.
Revenue (ttm)
112.04B
Revenue Growth
+17.84%
P/S Ratio
5.52
Revenue / Employee
375.99M
Employees
298
Market Cap
618.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 102.78B | 12.70B | 14.10% |
| Dec 31, 2023 | 90.08B | -389.58B | -81.22% |
| Dec 31, 2022 | 479.66B | -142.70B | -22.93% |
| Dec 31, 2021 | 622.36B | -9.15B | -1.45% |
| Dec 31, 2020 | 631.50B | 591.46B | 1,476.89% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,031.69B |
| Celltrion | 3,748.95B |
| ALTEOGEN | 158.06B |
| Yuhan | 2,165.44B |
| SK Biopharmaceuticals | 620.28B |
| Peptron | 5.18B |
| PharmaResearch | 449.81B |
| ABL Bio | 94.93B |